Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

ClinicalTrials.gov ID: NCT02642965

Public ClinicalTrials.gov record NCT02642965. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase I/II trial studies the side effects and best dose of liposome-encapsulated daunorubicin-cytarabine when given with fludarabine phosphate, cytarabine, and filgrastim and to see how well they work in treating younger patients with acute myeloid leukemia that has come back after treatment (relapsed) or is not responding to treatment (is refractory). Liposome-encapsulated daunorubicin-cytarabine is made up of two chemotherapy drugs, cytarabine and daunorubicin hydrochloride, and works to stop cancer cell growth by blocking the cells from dividing. Drugs used in chemotherapy, such as fludarabine phosphate and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Filgrastim may increase the production of blood cells and may help the immune system recover from the side effects of chemotherapy. Giving liposome-encapsulated daunorubicin-cytarabine followed by fludarabine phosphate, cytarabine, and filgrastim may be a better treatment for patients with relapsed acute myeloid leukemia and may cause fewer side effects to the heart, a common effect of other chemotherapy treatments for acute myeloid leukemia.

Study identification

NCT ID
NCT02642965
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Children's Oncology Group
Network
Enrollment
38 participants

Conditions and interventions

Eligibility (public fields only)

Age range
1 Year to 21 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2, 2016 (Actual)
Primary completion
Dec 31, 2018 (Actual)
Completion
Jun 30, 2023 (Actual)
Last update posted
Sep 8, 2023

2016 – 2023

United States locations

U.S. sites
67
U.S. states
34
U.S. cities
62
Facility City State ZIP Site status
Children's Hospital of Alabama Birmingham Alabama 35233 —
Phoenix Childrens Hospital Phoenix Arizona 85016 —
Arkansas Children's Hospital Little Rock Arkansas 72202-3591 —
Kaiser Permanente Downey Medical Center Downey California 90242 —
City of Hope Comprehensive Cancer Center Duarte California 91010 —
Loma Linda University Medical Center Loma Linda California 92354 —
Children's Hospital Los Angeles Los Angeles California 90027 —
Valley Children's Hospital Madera California 93636 —
UCSF Benioff Children's Hospital Oakland Oakland California 94609 —
Children's Hospital of Orange County Orange California 92868 —
University of California Davis Comprehensive Cancer Center Sacramento California 95817 —
UCSF Medical Center-Mission Bay San Francisco California 94158 —
Children's Hospital Colorado Aurora Colorado 80045 —
Connecticut Children's Medical Center Hartford Connecticut 06106 —
Alfred I duPont Hospital for Children Wilmington Delaware 19803 —
Children's National Medical Center Washington D.C. District of Columbia 20010 —
University of Florida Health Science Center - Gainesville Gainesville Florida 32610 —
Nemours Children's Clinic-Jacksonville Jacksonville Florida 32207 —
Nemours Children's Clinic - Pensacola Pensacola Florida 32504 —
Johns Hopkins All Children's Hospital St. Petersburg Florida 33701 —
Children's Healthcare of Atlanta - Egleston Atlanta Georgia 30322 —
Lurie Children's Hospital-Chicago Chicago Illinois 60611 —
Riley Hospital for Children Indianapolis Indiana 46202 —
Ascension Saint Vincent Indianapolis Hospital Indianapolis Indiana 46260 —
University of Kentucky/Markey Cancer Center Lexington Kentucky 40536 —
Eastern Maine Medical Center Bangor Maine 04401 —
Maine Children's Cancer Program Scarborough Maine 04074 —
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland 21287 —
Massachusetts General Hospital Cancer Center Boston Massachusetts 02114 —
Dana-Farber Cancer Institute Boston Massachusetts 02215 —
C S Mott Children's Hospital Ann Arbor Michigan 48109 —
Ascension Saint John Hospital Detroit Michigan 48236 —
University of Minnesota/Masonic Cancer Center Minneapolis Minnesota 55455 —
Mayo Clinic in Rochester Rochester Minnesota 55905 —
University of Mississippi Medical Center Jackson Mississippi 39216 —
Children's Mercy Hospitals and Clinics Kansas City Missouri 64108 —
Washington University School of Medicine St Louis Missouri 63110 —
Mercy Hospital Saint Louis St Louis Missouri 63141 —
Children's Hospital and Medical Center of Omaha Omaha Nebraska 68114 —
University of Nebraska Medical Center Omaha Nebraska 68198 —
Roswell Park Cancer Institute Buffalo New York 14263 —
NYU Winthrop Hospital Mineola New York 11501 —
Laura and Isaac Perlmutter Cancer Center at NYU Langone New York New York 10016 —
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York New York 10032 —
University of Rochester Rochester New York 14642 —
State University of New York Upstate Medical University Syracuse New York 13210 —
Mission Hospital Asheville North Carolina 28801 —
Children's Hospital Medical Center of Akron Akron Ohio 44308 —
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229 —
Rainbow Babies and Childrens Hospital Cleveland Ohio 44106 —
Nationwide Children's Hospital Columbus Ohio 43205 —
University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104 —
Oregon Health and Science University Portland Oregon 97239 —
Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104 —
Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania 15224 —
Saint Jude Children's Research Hospital Memphis Tennessee 38105 —
The Children's Hospital at TriStar Centennial Nashville Tennessee 37203 —
UT Southwestern/Simmons Cancer Center-Dallas Dallas Texas 75390 —
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston Texas 77030 —
Children's Hospital of San Antonio San Antonio Texas 78207 —
Primary Children's Hospital Salt Lake City Utah 84113 —
University of Vermont and State Agricultural College Burlington Vermont 05405 —
Children's Hospital of The King's Daughters Norfolk Virginia 23507 —
Seattle Children's Hospital Seattle Washington 98105 —
Providence Sacred Heart Medical Center and Children's Hospital Spokane Washington 99204 —
University of Wisconsin Carbone Cancer Center Madison Wisconsin 53792 —
Children's Hospital of Wisconsin Milwaukee Wisconsin 53226 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02642965, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 8, 2023 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02642965 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →